e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia
Keishi Sugino, Hirotaka Ono, Hiroshige Shimizu, Takeyuki Kurosawa, Keiko Matsumoto, Masahiro Ando, Kiyoshi Mori, Eiyasu Tsuboi, Sakae Homma, Kazuma Kishi
Source:
ERJ Open Res, 7 (1) 00196-2020; 10.1183/23120541.00196-2020
Journal Issue:
January
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Keishi Sugino, Hirotaka Ono, Hiroshige Shimizu, Takeyuki Kurosawa, Keiko Matsumoto, Masahiro Ando, Kiyoshi Mori, Eiyasu Tsuboi, Sakae Homma, Kazuma Kishi. Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia. ERJ Open Res, 7 (1) 00196-2020; 10.1183/23120541.00196-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
The classification, natural history and radiological/histological appearance of idiopathic pulmonary fibrosis and the other idiopathic interstitial pneumonias
Source: Eur Respir Rev 2008; 17: 108-115
Year: 2008
Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia
Source: Eur Respir J 2005; 25: 528-533
Year: 2005
Cyclosporine A in the treatment of idiopathic pulmonary fibrosis/usual interstitial pneumonia
Source: Eur Respir J 2002; 20: Suppl. 38, 62s
Year: 2002
Architectural remodelling in idiopathic interstitial pneumonias: fibrosis or fibroelastosis?
Source: Eur Respir J 2004; 24: Suppl. 48, 557s
Year: 2004
Antifibrotic choice in idiopathic pulmonary fibrosis
Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF)
Year: 2018
Association between antifibrotic medications and pneumothorax or pneumomediastinum in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Idiopathic pulmonary haemosiderosis revisited
Source: Eur Respir J 2004; 24: 162-169
Year: 2004
Clinical features of usual interstitial pneumonia-correlation between idiopathic pulmonary fibrosis and connective tissue disease associated with usual interstitial pneumonia
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia
Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials
Year: 2017
Bronchiolitis as a component in idiopathic pulmonary fibrosis and idiopathic interstitial pneumonias: clinico-pathological characteristics
Source: Eur Respir J 2004; 24: Suppl. 48, 534s
Year: 2004
Clinical significance of histological classification of idiopathic interstitial pneumonia
Source: Eur Respir J 2002; 19: 275-283
Year: 2002
Non-IPF idiopathic interstitial pneumonias
Source: School Course 2014 - Interstitial lung diseases
Year: 2014
Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia
Source: Eur Respir J 2002; 19: 1114-1118
Year: 2002
Immunogenetic background of children´s idiopathic interstitial pneumonias and adult idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Year: 2010
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
Clinical features of patients with idiopathic pulmonary upper lobe-dominant fibrosis
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis
Source: Eur Respir J 2001; 18: 43S-55S
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept